Ayobola Abolape Iyanda

Ayobola Abolape Iyanda

Auto-generated profile, based on publicly available information

Ayobola Abolape Iyanda

Department of Chemical Pathology, Faculty of Basic Clinical Sciences, Ladoke Akintola University of Technology (LAUTECH), Ogbomoso, Oyo State, Nigeria

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2023 in Universal Journal of Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
OAOlufunso B. Adeoye
Olufunso B. Adeoye
AIAbolape A. Iyanda
Abolape A. Iyanda
MDMichael Oluwatoyin Daniyan
Michael Oluwatoyin Daniyan
DADavid A. Adeoye
David A. Adeoye
OOOmoyiola L. Olajide
Omoyiola L. Olajide
OOOlajoju M. Olatinwo
Olajoju M. Olatinwo
Background and Aim: Chronic hyperglycemia, oxidative stress, and dyslipidemia usually predispose to cardiac aberrations. Certain honey samples have been reported to worsen glycemic control or proven to be cardiotoxic. The study sought to elucidate the roles of Nigerian bitter honey in experimental diabetes. Experimental Procedures: Diabetes was induced in adult female Wistar rats (90–110g) by single administration of streptozotocin (65 mg/kg body weight, i.p.). Rats were randomly allocated into six groups (n= 8). Bitter honey (50 mg/kg) and metformin (100 mg/kg) were orally administered daily for 28 days. Animals were sacrificed on day 29 and blood samples were obtained via cardiac puncture. Lipid profile and lipid peroxidation analysis were carried out using standard methods. Atherogenic, coronary, and cardiovascular risk indexes were calculated. Heart, pancreas, and lung tissues were harvested and subjected to histopathological assessment. Data were analyzed using one way ANOVA, and statistical significant level was set at p<0.05. Result and Discussion: Bitter honey treatment in the diabetic animals significantly reduced hyperglycemia, triglyceride, total cholesterol, low-density lipoprotein, malondialdehyde, and cardiovascular risk levels (p<0.05). Correspondingly, HDL and reduced glutathione levels were significantly higher (p<0.05). Bitter honey preserved the histoarchitectural integrity of the cardiomyocytes and lungs tissue. Conclusion: The bitter honey is a highly remarkable repository of naturally occurring bioactive compounds that can potentially modulate downstream biochemical pathways of hyperglycemia, dyslipidemia and lipid peroxidation. The bitter honey may therefore be a promising new source of anti-diabetic and cardio protective nutraceuticals.               Peer Review History: Received: 9 February 2023; Revised: 7 March; Accepted: 29 April 2023, Available online: 15 May 2023 Academic Editor: Dr. Amany Mohamed Alboghdadlyorcid22.jpg, Ibn Sina National College for Medical Studies in Jeddah, Saudi Arabia, amanyalboghdadly@gmail.com  Received file: 6.gif                            Reviewer's Comments:download_logo_r_29189.gif Average Peer review marks at initial stage: 6.0/10 Average Peer review marks at publication stage: 7.0/10 Reviewers: orcid22.jpgDr. Sangeetha Arullappan, Universiti Tunku Abdul Rahman, Malaysia, sangeetha@utar.edu.my orcid22.jpgDr. Rawaa Souhil Al-Kayali, Aleppo University, Syria, rawah67@hotmail.com

12 September 2025 in Cardiology and Angiology: An International Journal
Verified
Journal Article
Closed access
SOSamson Ojedokun
Samson Ojedokun
JAJoel Olufunminiyi Akande
Joel Olufunminiyi Akande
AIAyobola Abolape Iyanda
Ayobola Abolape Iyanda
Background: Myocardial infarction may go undetected as a catastrophic event leading to hemodynamic deterioration and sudden death. The role of cardiac makers in the prompt diagnosis of acute myocardial infarction AMI has been established especially in patient presenting with clinical features coronary artery disease, however, the use of known cardiac biomarkers in the risk assessment of MI in newly diagnosed patients with hypertension is unpopular. This study aimed to assess the risk for myocardial infarction using cardiac troponin I and Atherogenic indices in newly diagnosed drug naïve patients with hypertension. Methods: The cross-sectional descriptive study was conducted among one hundred and seventeen subjects ≥18years. Anthropometric measurements and physical examination were done. Atherogenic indices for cardiovascular risk were estimated alongside biochemical parameters including cardiac Troponin I, lipid profiles, urea/creatinine and blood glucose. Data obtained were analysed using SPSS version 26, at p <0.05. Results: Most of the respondents were within the fourth decade of life, mean age of 45.24 ± 15.89 years. There was a preponderance for female sex with a male to female ratio of 1:1.2. Commonly reported clinical symptoms were palpitations, chest pain, shoulder pain and fatigue. The prevalence of cardiac troponin I (cTnI) was 10.3%, overall dyslipidaemia prevalence 97.4%, commonest was hypertriglyceridemia, and commonest pattern was mixed dyslipidaemia 70.2%. The majority with high cTnI had high CVD risk classified with AIP and CRR1. AIP demonstrated strong positive correlations with CRR1 P<0.05. And cTnI is a strong predictor with good discrimination (AUC = 0.762) and balanced sensitivity (81.42%) and specificity (75%). Conclusion: Cardiac troponin I showed good risk assessment value. The presence of cTnI activities clearly indicates an ongoing myocadiac structural changes, demonstrating a strong predictive strength. Also, AIP was identified as most important atherogenic index in drug naïve hypertensives.